Hyderabad: Cipla Ltd will produce the primary three-in-one cocktail anti-AIDS medicine used for children. This accompanies the USFDA clearing a combining quantity of Boehringer Ingelheim’s Viramune, GlaxoSmithKline’s Epivir (or lamivudine) and Bristol-Myers Squibb’s Zerit (or stavudine), which are anti-retrovirals or drugs that fight back AIDS.

The commendation came under the US President’s Emergency Plan for AIDS Relief, or Pepfar, a $15 billion, 5-year plan to clash the threat in over 15 countries.

Amar Lulla, MD, Cipla stated, “The problem is massive and children have been by far ignored till now as there were no right dosages available for supply.”

He also said that this is the foremost pediatric quantity of the grouping and provided that only 50,000 children are under treatment presently, the aim is to get to 10 times the number.

Lulla added that money making was not the purpose here.

This plan is exceptional in the sense generics manufacturers such as Cipla can produce still-under-patent medicines for supply to countries frequently in sub-Saharan Africa that are the worst affected by HIV/AIDS at highly subsdised prices.